Alnylam Pharmaceuticals, Inc. (ALNY)
Nasdaq · Cambridge, Massachusetts, USA · Founded 2002 · CEO Yvonne Greenstreet
Valuation summary
$183.53 fair value versus $147.82 in the market, a difference of +24.2%. Rated Buy.
| Fair value per share | $183.53 |
| Current share price | $147.82 |
| Upside / downside | +24.2% |
| Bear case | $115.96 |
| Bull case | $279.97 |
| Discount rate (WACC) | 10.4% |
| Terminal growth | 3.50% |
| Market capitalisation | $20B |
| EV / Sales | 4.3x |
About Alnylam Pharmaceuticals, Inc.
Founded in 2002 to turn RNA interference, a Nobel Prize-winning discovery, into medicines. Yvonne Greenstreet has been chief executive since 2022. RNAi drugs silence the gene that produces a harmful protein, often with injections only a few times a year. Alnylam's largest product, Amvuttra, was approved in 2025 to treat ATTR amyloidosis with cardiomyopathy, a large heart disease market, which has driven very fast sales growth and pushed the company into profitability.
Investment case
- Amvuttra's cardiomyopathy launch is one of the strongest in biotech.
- A platform that has produced several approved drugs, with more in the pipeline, including for hypertension.
- Turning profitable, with margins set to rise quickly.
Key risks
- Competition in ATTR cardiomyopathy from Pfizer's tafamidis and BridgeBio's acoramidis.
- Heavy reliance on one drug family.
- Drug pricing reform could affect high-priced rare disease medicines.
Recent developments
- 2026-10-29 · Q3 product revenue up 52% on AMVUTTRA demand in ATTR cardiomyopathy; EPS boosted by a $1.9bn tax benefit source
Revenue by segment
| TTR franchise (Amvuttra, Onpattro) | 75% |
| Rare disease products | 15% |
| Collaborations & royalties | 10% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $7.0B | $0.7B |
| Year 2 | $9.6B | $1.0B |
| Year 3 | $12.2B | $1.4B |
| Year 4 | $14.4B | $1.7B |
| Year 5 | $15.8B | $1.9B |
What the street says
Viewed as one of the few large biotechs with a long growth runway; the debate is market share in cardiomyopathy.
Comparable companies: NTRA · TEM · DXCM · HIMS · ARGX · HUM · GEHC · BSX
Open the interactive model, price chart and sensitivity grid →